LEESBURG, Va. / Jul 11, 2023 / Business Wire / Stryker (NYSE: SYK), one of the world’s leading medical technology companies, has commercially launched its Q Guidance System with Cranial Guidance Software to provide surgeons with an image-based planning and intraoperative guidance system that assists in positioning instruments and identifying patient anatomy during cranial surgery. The software can be used for craniotomies, skull base and transsphenoidal procedures, shunt placements, and biopsies.
“With Cranial Guidance Software powered by Q, neurosurgeons have more surgical planning and guidance capabilities than ever before, with a special focus on biopsies and shunt placements,” said Robbie Robinson, president of Stryker’s Spine division. “This technology has the potential to become the standard of care and a possible means to increase accuracy and efficiency in the operating room.”
The Q Guidance System with Cranial Guidance Software uses both active and passive tracking technology to provide groundbreaking planning and guidance capabilities that include:
“With Stryker’s new camera technology, we were able to quickly register patients using the CranialMask Tracker,” said Dr. J.D. Day, M.D. of UAMS Health in Little Rock, Arkansas. “The new user interface and workflows are slick, and our staff loves the intuitive new views like 3D targeting and the new skull stripping feature.”
The Q Guidance System with Cranial Guidance Software was used at six early product surveillance sites in May 2023.
Learn more about this new technology at strykeronegiantleap.com.
References:
1. Stryker data on file.
About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually.
More information is available at www.stryker.com.
Last Trade: | US$346.50 |
Daily Change: | -0.17 -0.05 |
Daily Volume: | 1,324,316 |
Market Cap: | US$132.090B |
March 04, 2025 March 03, 2025 January 28, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load